These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38764645)

  • 1. Molecular Dynamic Simulation To Reveal the Mechanism Underlying MGL-3196 Resistance to Thyroxine Receptor Beta.
    Lu Y; Chen C; Zhuang D; Qian L
    ACS Omega; 2024 May; 9(19):20957-20965. PubMed ID: 38764645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders.
    Saponaro F; Sestito S; Runfola M; Rapposelli S; Chiellini G
    Front Med (Lausanne); 2020; 7():331. PubMed ID: 32733906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
    Li Q; Yao B; Zhao S; Lu Z; Zhang Y; Xiang Q; Wu X; Yu H; Zhang C; Li J; Zhuang X; Wu D; Li Y; Xu Y
    J Med Chem; 2022 May; 65(10):7193-7211. PubMed ID: 35507418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-Specific Transport and Thyroid Hormone Receptor Isoform Selectivity Account for Hepatocyte-Targeted Thyromimetic Action of MGL-3196.
    Hönes GS; Sivakumar RG; Hoppe C; König J; Führer D; Moeller LC
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis.
    Wirth EK; Puengel T; Spranger J; Tacke F
    Expert Rev Endocrinol Metab; 2022 Sep; 17(5):425-434. PubMed ID: 35957531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to thyroid hormone caused by two mutant thyroid hormone receptors beta, R243Q and R243W, with marked impairment of function that cannot be explained by altered in vitro 3,5,3'-triiodothyroinine binding affinity.
    Yagi H; Pohlenz J; Hayashi Y; Sakurai A; Refetoff S
    J Clin Endocrinol Metab; 1997 May; 82(5):1608-14. PubMed ID: 9141558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid Hormone Analogues: An Update.
    Zucchi R
    Thyroid; 2020 Aug; 30(8):1099-1105. PubMed ID: 32098589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
    Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of thyroid hormone receptor beta is not detrimental for non-alcoholic steatohepatitis progression.
    Lopez-Alcantara N; Oelkrug R; Sentis SC; Kirchner H; Mittag J
    iScience; 2023 Oct; 26(10):108064. PubMed ID: 37822510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid Hormone Receptor-β Agonists in NAFLD Therapy: Possibilities and Challenges.
    Li L; Song Y; Shi Y; Sun L
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1602-1613. PubMed ID: 36746649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics.
    Alshehade SA
    Clin Res Hepatol Gastroenterol; 2024 May; 48(7):102377. PubMed ID: 38772519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.
    Karim G; Bansal MB
    touchREV Endocrinol; 2023 May; 19(1):60-70. PubMed ID: 37313239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.
    Harrison SA; Bashir M; Moussa SE; McCarty K; Pablo Frias J; Taub R; Alkhouri N
    Hepatol Commun; 2021 Apr; 5(4):573-588. PubMed ID: 33860116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological Interactions Between Mutant Thyroid Hormone Receptors and Corepressors and Their Modulation by a Thyroid Hormone Analogue with Therapeutic Potential.
    Harrus D; Déméné H; Vasquez E; Boulahtouf A; Germain P; Figueira AC; Privalsky ML; Bourguet W; le Maire A
    Thyroid; 2018 Dec; 28(12):1708-1722. PubMed ID: 30235988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five new families with resistance to thyroid hormone not caused by mutations in the thyroid hormone receptor beta gene.
    Pohlenz J; Weiss RE; Macchia PE; Pannain S; Lau IT; Ho H; Refetoff S
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3919-28. PubMed ID: 10566629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis.
    Javanbakht M; Fishman J; Moloney E; Rydqvist P; Ansaripour A
    Pharmacoecon Open; 2023 Jan; 7(1):93-110. PubMed ID: 36104546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor.
    Estébanez-Perpiñá E; Arnold LA; Jouravel N; Togashi M; Blethrow J; Mar E; Nguyen P; Phillips KJ; Baxter JD; Webb P; Guy RK; Fletterick RJ
    Mol Endocrinol; 2007 Dec; 21(12):2919-28. PubMed ID: 17823305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the roles of mutations in thyroid hormone receptor-β by a bacterial biosensor system.
    Shi C; Meng Q; Wood DW
    J Mol Endocrinol; 2014 Feb; 52(1):55-66. PubMed ID: 24174637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review.
    Guirguis E; Grace Y; Bolson A; DellaVecchia MJ; Ruble M
    Pharmacotherapy; 2021 Mar; 41(3):315-328. PubMed ID: 33278029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
    Kannt A; Wohlfart P; Madsen AN; Veidal SS; Feigh M; Schmoll D
    Br J Pharmacol; 2021 Jun; 178(12):2412-2423. PubMed ID: 33655500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.